SCHEMBL24508441

SCHEMBL24508441

CCCCCNC[C@H]1OCc2ccc3c(c21)OCO3

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 2/20 0.39
MTNR1B P49286 2/20 0.39
TRPV1 Q8NER1 1/20 0.37
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA7 P36544 1/20 0.35
CHRNA4 P43681 1/20 0.35
DRD2 P14416 3/20 0.35
DRD1 P21728 2/20 0.35
DRD4 P21917 1/20 0.35
DRD5 P21918 1/20 0.35
DRD3 P35462 1/20 0.35
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3064191 0.70 MTNR1A (0.65) MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3
SCHEMBL32670725 0.69 TAAR1 (0.47) MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3
SCHEMBL30360651 0.69 TAAR1 (0.47) MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3
SCHEMBL30360707 0.69 TAAR1 (0.47) MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3
SCHEMBL19812780 0.69 TAAR1 (0.47) MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3
SCHEMBL19821165 0.67 MTNR1A (0.46) MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3
SCHEMBL23016564 0.65 MTNR1A (0.47) MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3
SCHEMBL19813056 0.61 TAAR1 (0.43) MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3
SCHEMBL19813086 0.61 TAAR1 (0.43) MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3
SCHEMBL32670720 0.61 TAAR1 (0.43) MTNR1AMTNR1BCHRNB2CHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220185799-A1 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2022-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220185799-A1 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS CNR1, HCRTR1, CNR2 MTNR1A 72/4885MTNR1B 62/4885TRPV1 2804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.